Divi's Laboratories Performance
52 Week Range
- Open Price
- Previous Close
Start SIP in Divi's LaboratoriesStart SIP
Divi's Laboratories Investment Rating
Divis Laboratories (Nse) has an operating revenue of Rs. 7,767.51 Cr. on a trailing 12-month basis. An annual revenue de-growth of -11% needs improvement, Pre-tax margin of 30% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 5% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
|Indicator||Mar 2023||Dec 2022||Sep 2022||Jun 2022||Mar 2022|
|Oper Rev Qtr Cr||1,908||1,690||1,823||2,204||2,495|
|Operating Expenses Qtr Cr||1,419||1,280||1,214||1,366||1,399|
|Operating Profit Qtr Cr||489||409||609||838||1,096|
|Depreciation Qtr Cr||87||87||85||83||81|
|Interest Qtr Cr||0||0||0||0||0|
|Tax Qtr Cr||149||128||116||152||183|
|Net Profit Qtr Cr||319||311||487||692||883|
Divi's Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Divi's Laboratories Resistance and Support
|MACD Single Line||80.28|
Divi's Laboratories Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Divi's Laboratories Result Highlights
Divi's Laboratories Synopsis
NSE-Medical-Generic DrugsDivi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 7625.30 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2023. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
|Shares in Float||12.74|
|No of funds||751|
|U/D Vol ratio||1.4|
|LTDebt / Equity|
|Foreign Portfolio Investors||14.67%||15.15%||15.4%||16.52%|
|Financial Institutions/ Banks||0.11%||0.12%||0.11%||0.09%|
Divi's Laboratories Management
|Dr. Ramesh B V Nimmagadda||Non Exe.Chairman&Ind.Director|
|Dr. Murali K Divi||Managing Director|
|Dr. Kiran S Divi||WholeTime Director & CEO|
|Ms. Nilima Prasad Divi||Whole Time Director|
|Mr. Madhusudana Rao Divi||Whole Time Director|
|Mr. N V Ramana||Executive Director|
|Mr. K V K Seshavataram||Independent Director|
|Dr. G Suresh Kumar||Independent Director|
|Mr. R Ranga Rao||Independent Director|
|Prof. Sunaina Singh||Independent Director|
|Dr. S Ganapaty||Independent Director|
|Mr. K V Chowdary||Independent Director|
Divi's Laboratories Forecast
Divi's Laboratories Corporate Action
Divi's Laboratories FAQs
What is Share Price of Divi's Laboratories ?
Divi's Laboratories share price is ₹3442 As on 09 June, 2023 | 13:19
What is the Market Cap of Divi's Laboratories ?
The Market Cap of Divi's Laboratories is ₹91375.6 Cr As on 09 June, 2023 | 13:19
What is the P/E ratio of Divi's Laboratories ?
The P/E ratio of Divi's Laboratories is 50.1 As on 09 June, 2023 | 13:19
What is the PB ratio of Divi's Laboratories ?
The PB ratio of Divi's Laboratories is 7.2 As on 09 June, 2023 | 13:19
What does Divis Laboratories do?
Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.
Is Divis Laboratories good for the long term?
Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.
Is Divis Laboratories debt-free?
Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
Who is the owner of Divis Laboratories?
Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).
How to buy Divis Laboratory?
You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.